SOURCE: CTD Holdings, Inc.

CTD Holdings, Inc. Logo

March 17, 2015 07:00 ET

CTD Holdings Names Caroline Hastings, M.D., to Scientific Advisory Board

Dr. Hastings Pioneered Treatment of Niemann-Pick Type C Using Trappsol® Cyclo™

ALACHUA, FL--(Marketwired - March 17, 2015) - CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that develop cyclodextrin-based treatments, including the orphan drug designated Trappsol® Cyclo™, today announced the appointment of Caroline Hastings, M.D., to the company's Scientific Advisory Board. Dr. Hastings joins Dr. Sharon Hrynkow, President of Global Virus Network and Founder and Managing Partner of Global Health Consulting LLC, in advising the Company.

Dr. Hastings has been on the faculty of UCSF Benioff Children's Hospital Oakland since 1992. She is Board Certified in Pediatric Hematology-Oncology. Dr. Hastings is a dedicated clinician and has been a leader in establishing a hematology specialty outreach clinic and practice in Northern Nevada. Additionally, Dr. Hastings is the Director of the fellowship training program in Pediatric Hematology-Oncology at UCSF Benioff Children's Hospital Oakland and is on the board of trustees for the American Society of Pediatric Hematology-Oncology in which she serves as an advocate for childhood cancer research and education.

In 2008, Dr. Hastings worked with the Hempel family to pioneer the treatment of Niemann-Pick Type C using cyclodextrin-based I.V. infusions to remove excess cholesterol from the patients. CTD provided the first generation of its Trappsol® Cyclo™ orphan drug product to Dr. Hastings and the Hempel family, and assisted them in filing the first Investigational New Drug protocol with the U.S. FDA, authorizing compassionate use of the product for the Hempel's children. In 2010 Dr. Hastings was granted Orphan Drug status for Trappsol® Cyclo™ to use in the treatment of Niemann-Pick Type C, a rare and tragic disease.

"I am especially gratified that Dr. Hastings is joining our Scientific Advisory Board," said Dr. Jeffrey Tate, President and CEO of CTD. "She has been a tireless pioneer in the treatment of children with Niemann-Pick Type C, and her immense experience and clinical expertise will be invaluable to our group of advisors."

"It is an honor to be invited to join this prestigious organization and participate in the development of this drug for patients with Niemann-Pick Type C," said Dr. Hastings. "The first kids who received this drug, and their parents, have entrusted themselves to us to develop this drug so that future patients may benefit with an improved quality of life. Now, we are in a position to move forward."

About the Company: 
CTD Holdings, Inc. is a family of biotechnology growth companies based on cyclodextrin chemistry. Its individual divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies involved in research, pharmaceutical, medical device, cosmetics and nutrition markets. Sphingo Biotechnology, Inc. is developing Trappsol® Cyclo™, an orphan drug designated product, for the treatment of Niemann Pick Type C, a rare and fatal genetic disease in young children. NanoSonic Products, Inc. operates the world's only cGMP pulse drying facility for the production of UltraPure™ cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes. CTD, Inc. supplies cyclodextrins to biotechnology and life science researchers around the globe from the world's largest catalog of cyclodextrins. The companies offer a wide variety of cyclodextrin related manufacturing services to worldwide customers, including custom formulation, manufacturing, and commercial scale supply of pharmaceutical grade cyclodextrin complexes. For additional information, visit the Company's websites: www.ctd-holdings.com and www.cyclodex.com

Safe Harbor Statement:
This press release contains "forward-looking statements" about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the Company's future performance include the Company's ability to obtain additional capital to expand operations as planned, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing food and pharmaceutical grade products. These and other risk factors are described from time to time in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's reports on Forms 10-K and 10-Q. Unless required by law, the Company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Contact Information